...
首页> 外文期刊>The Journal of molecular diagnostics: JMD >FOXL2 402C > G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor
【24h】

FOXL2 402C > G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor

机译:可以在成人型颗粒细胞肿瘤患者的循环肿瘤DNA中鉴定FOXL2 402C> G突变

获取原文
获取原文并翻译 | 示例

摘要

Adult granulosa cell tumors (AGCTs) of the ovary are molecularly characterized by the pathognomonic FOXL2 402C>G (C134W) mutation. To improve diagnostics and follow-up, we developed a specific digital droplet PCR (ddPCR) assay to detect the FOXL2 mutation in the circulating tumor DNA (ctDNA) of AGCT patients. Optimization of the ddPCR assay was performed using a TaqMan primer/probe with the RainDance RainDrop digital PCR system. The ddPCR assay was performed on circulating cell-free DNA extracted from 120 serial plasma samples collected prospectively from 35 AGCT patients. The ddPCR assay included a preamplification step that is sensitive and specific for detecting the FOXL2-mutated ctDNA at levels as low as 0.05%. FOXL2 ctDNA mutations were detected in the plasma of 12 of 33 AGCT patients (36%), with both primary (6 of 17, 35%) and recurrent (6 of 31, 19%) tumors. The median tumor size was significantly larger in ctDNA mutation positive compared with mutation-negative samples (13.5 cm versus 7.5 cm; P = 0.003). The ctDNA FOXL2 mutation was detected in four patients without clinical disease, of which one relapsed during follow-up. As proof of concept, we established that specific molecular diagnosis of AGCT and detection of AGCT recurrence can be achieved noninvasively using ctDNA FOXL2 mutation testing. Further studies are needed to determine the clinical value of ctDNA mutation testing.
机译:卵巢的成年颗粒细胞肿瘤(AgCTS)的特征在于分子表征,其特征在于病例FOXL2 402C> G(C134W)突变。为了改善诊断和随访,我们开发了一种特定的数字液滴PCR(DDPCR)测定以检测AGCT患者的循环肿瘤DNA(CTDNA)中的FOXL2突变。使用Taqman Primer /探针进行DDPCR测定的优化,其中较拖车雨滴数字PCR系统。对从预期收集的120个序列等离子体样品中提取的循环无细胞DNA进行DDPCR测定,从预期从35例AGCT患者中收集。 DDPCR测定包括前置放大步骤,其敏感,并且具体用于检测低至0.05%的水平的FoxL2突变的CTDNA。在33例AGCT患者的12个血浆中检测到FOXL2 CTDNA突变(36%),伯次(6个,35%)和复发(31,19%)肿瘤的血浆。与突变阴性样品相比,CTDNA突变阳性中位数肿瘤大小明显较大(13.5cm与7.5cm; p = 0.003)。在四个没有临床疾病的患者中检测到CTDNA FOXL2突变,其中一个在随访期间复发。作为概念的证据,我们建立了agct的特定分子诊断和agct复发的检测可以使用CTDNA FOXL2突变试验来实现。需要进一步的研究来确定CTDNA突变检测的临床价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号